Dr. Mark R. Wakefield, MD
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- University of Missouri, Columbia School of Medicine (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 452
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: University of Missouri, Columbia School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
MO license 106072
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Missouri Health Care Columbia, MO
- Boone Hospital Center Columbia, MO
- Lake Regional Health System Osage Beach, MO
- Phelps County Regional Medical Center Rolla, MO
Medical groups
- The Curators of the University of Missouri (1,131 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 452
- Services billed
- 1,202
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 234 | 172 |
| Established patient office or other outpatient visit, 20-29 minutes | 137 | 122 |
| Diagnostic exam of bladder and urethra using an endoscope | 76 | 56 |
| New patient office or other outpatient visit, 45-59 minutes | 42 | 42 |
| Simple change of bladder tube | 33 | 12 |
| Imaging of urinary tract following injection of a contrast agent | 28 | 19 |
| Insertion of stent in ureter using an endoscope | 27 | 18 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 19 | 11 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 17 | 12 |
| New patient office or other outpatient visit, 30-44 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Columbia, MO | 336 |
| Finasteride Other prescribers in Columbia, MO | 260 |
| Myrbetriq (mirabegron) Other prescribers in Columbia, MO | 109 |
| Oxybutynin Chloride Other prescribers in Columbia, MO | 73 |
| Alfuzosin Hcl Er (alfuzosin hcl) Other prescribers in Columbia, MO | 72 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Columbia, MO | 62 |
| Methenamine Hippurate Other prescribers in Columbia, MO | 62 |
| Doxazosin Mesylate Other prescribers in Columbia, MO | 50 |
| Solifenacin Succinate Other prescribers in Columbia, MO | 39 |
| Nitrofurantoin Mono-Macro (nitrofurantoin monohyd/m-cryst) Other prescribers in Columbia, MO | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 46 payments worth $1,747 in total to this clinician.
| Boston Scientific Corporation | $713 |
|---|---|
| Endo USA, Inc. | $159 |
| Histosonics, Inc. | $150 |
| Medtronic, Inc. | $144 |
| Coloplast Corp | $103 |
| Urogen Pharma, Inc. | $86.06 |
| Ferring Pharmaceuticals Inc. | $85.50 |
| Abc Home Medical Supply, Inc. | $47.63 |
| Food and Beverage | $1,747 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $29,109 in research payments for these studies, mostly to the institutions running them.
- A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)
Janssen Research & Development, LLC - A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer INTerpath-011.
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.